Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 6/20 | 0.59 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 6/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.44 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.41 |
| ▸ | STK4 | Q13043 | 2/20 | 0.41 |
| ▸ | STK3 | Q13188 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000846 | 0.88 | AKT2 (0.66) | AKT2GSK3BSLC6A4SLC6A3AKT1 | |
| SCHEMBL3491404 | 0.82 | AKT2 (0.45) | AKT2GSK3B | |
| SCHEMBL1001928 | 0.81 | AKT2 (0.56) | AKT2GSK3BSLC6A4SLC6A3DPP4 | |
| SCHEMBL1001801 | 0.80 | AKT2 (0.77) | AKT2GSK3BAKT1RPS6KB1 | |
| SCHEMBL2781812 | 0.79 | RPS6KB1 (0.64) | AKT2GSK3BSLC6A4SLC6A3DPP4 | |
| SCHEMBL14385572 | 0.77 | AKT2 (0.48) | AKT2GSK3BSLC6A4SLC6A3DPP4 | |
| SCHEMBL2779105 | 0.77 | RPS6KB1 (0.58) | AKT2GSK3BSLC6A4RPS6KB1 | |
| SCHEMBL2783501 | 0.76 | AKT2 (0.65) | AKT2GSK3BAKT1RPS6KB1 | |
| SCHEMBL2779254 | 0.74 | AKT2 (1.00) | AKT2GSK3BAKT1RPS6KB1 | |
| SCHEMBL1003089 | 0.73 | AKT2 (0.51) | AKT2AKT1RPS6KB1STK4STK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| WO-2007125325-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | PKN2, PKN1, CSNK1A1 | AKT2 71/4885GSK3B 31/4885SLC6A4 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.